-
公开(公告)号:US20100184813A1
公开(公告)日:2010-07-22
申请号:US12642195
申请日:2009-12-18
IPC分类号: A61K31/4245 , C07D271/113 , A61P3/04 , A61P3/10
CPC分类号: B64D39/00 , C07D271/113
摘要: DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein n is 0, 1, 2 or 3, R is independently selected from fluoro, chloro, bromo, trifluoromethyl, methoxy, difluoromethoxy and trifluoromethoxy and Z is carboxy or a mimic or bioisostere thereof, hydroxyl, hydroxymethyl, or —CONRbRc wherein Rb and Rc are independently selected from hydrogen and (1-4C)alkyl, which (1-4C)alkyl group may be optionally substituted by carboxy or a mimic or bioisostere thereof.
摘要翻译: 已经描述了式(I)的DGAT-1抑制剂化合物及其药学上可接受的盐以及药物组合物,其制备方法及其用于治疗例如肥胖症,其中n为0,1,2或3,R 独立地选自氟,氯,溴,三氟甲基,甲氧基,二氟甲氧基和三氟甲氧基,Z是羧基或其模拟或生物电子等排物,羟基,羟甲基或-CONRbRc,其中Rb和Rc独立地选自氢和(1-4C) 烷基,其中(1-4C)烷基可以任选被羧基或其模拟物或生物电子等排物取代。